- Apology. // CMAJ: Canadian Medical Association Journal Supplement;7/3/2007, Vol. 177 Issue 1, p66
A correction to the article "Debate Begins Over Public Funding for HPV Vaccine" is presented.
- Apology. // CMAJ: Canadian Medical Association Journal;7/3/2007, Vol. 177 Issue 1, p66
A correction to the article "Debate begins over public funding for HPV vaccine" that was published in March 27, 2007 issue is presented.
- Corrections. // CMAJ: Canadian Medical Association Journal Supplement;4/24/2007, Vol. 176 Issue 9, p1310
Corrections to the articles "A Comprehensive View of Sex-Specific Issues Related to Cardiovascular Disease" and "Debate Begins Over Public Funding for HPV Vaccine," both of which appeared in previous issues, are presented.
- Texas plans for mandatory HPV vaccination fuel controversy. // PharmacoEconomics & Outcomes News;2/24/2007, Issue 522, p10
The article reports on a debate over plans for mandatory human papillomavirus (HPV) vaccination in Texas. Governor Rick Perry has employed an executive order to require that girls aged 11 and 12 years receive the vaccine, beginning in September 2008. Conservative groups opposing the order claim...
- Another Look at the Human Papillomavirus Vaccine Experience in Canada. Man, Catherine L.; Deber, Raisa B.; Guttmann, Astrid; McGeer, Allison; Krahn, Murray // American Journal of Public Health;Oct2011, Vol. 101 Issue 10, p1850
Policy debates about immunization frequently focus on classic trade-offs between individual versus collective wellbeing. Publicly funded immunization programs are usually justified on the basis of widespread public benefit with minimal individual risk. We discuss the example of the policy...
- HPV vaccination likely to be cost effective in China. // PharmacoEconomics & Outcomes News;Mar2015, Vol. 724 Issue 1, p12
The article reports that according to a stud, published in the journal "Vaccine," publicly-funded human papillomavirus (HPV) vaccination in China in women would is cost effective.
- Human papillomavirus vaccination policy: a public health ethics perspective. MIN-CHIN CHAN; SHEN-KANG CHIU; KEVIN CHIEN-CHANG WU; CHI-TAI FANG // Taiwan Journal of Publich Health / Taiwan Gong Gong Wei Sheng Za;Aug2013, Vol. 32 Issue 4, p309
Human papillomavirus (HPV) is a major factor in the etiology of cervical cancer. Two HPV vaccines, HPV4 (against HPV types 6, 11, 16, and 18) and HPV2 (against HPV 16 and 18), have been approved for adolescent girls younger than age 26. Due to concerns about the price, duration of protection,...
- HPV Vaccine utilization, Alberta 2008/09-2013/14 School year. Liu, Xianfang C.; Bell, Christopher A.; Simmonds, Kimberley A.; Russell, Margaret L.; Svenson, Lawrence W. // BMC Infectious Diseases;1/13/2016, Vol. 16, p1
Background:In Canada both bivalent (bHPV) vaccine and quadrivalent HPV vaccine (qHPV) are authorized for use. In Alberta, while both vaccines are available for private purchase, only qHPV is publicly funded for school girls in grades 5 and 9 as of 2013. We describe HPV vaccine...
- A LUTHERAN DEFENSE OF THE HPV VACCINE. SWANSON, THOR // Ethics & Medicine: An International Journal of Bioethics;Spring2014, Vol. 30 Issue 1, p35
Over the course of the last 7 years there has been considerable debate in the media, the public, and especially in the Conservative Protestant and Catholic communities over the appropriateness of the fairly new Human Papilloma Virus (HPV) vaccine. For instance, this author attended a Christian...
- HPV jab could roll out to over-18s. Tanday, Sanjay // GP: General Practitioner;4/18/2008, p3
The article reports on the roll-out of human papillomavirus (HPV) vaccination programme to women over the age of 18 in Great Britain. Shona Robinson, public health minister for Scotland, says that the vaccine is beneficial to older women, particularly those with limited exposure to HPV through...